UA110463C2 - ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ 4-{[9-ХЛОР-7-(2-ФТОР-6-МЕТОКСИФЕНІЛ)-5Н-ПІРИМІДО[5,4-d][2]БЕНЗАЗЕПІН-2-ІЛ]АМІНО}-2-МЕТОКСИБЕНЗОЙНОЇ КИСЛОТИ ДЛЯ ЛІКУВАННЯ РАКУ Й ІНШИХ ЗАХВОРЮВАНЬ І ПОРУШЕНЬ СТАНУ ЗДОРОВ'Я - Google Patents

ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ 4-{[9-ХЛОР-7-(2-ФТОР-6-МЕТОКСИФЕНІЛ)-5Н-ПІРИМІДО[5,4-d][2]БЕНЗАЗЕПІН-2-ІЛ]АМІНО}-2-МЕТОКСИБЕНЗОЙНОЇ КИСЛОТИ ДЛЯ ЛІКУВАННЯ РАКУ Й ІНШИХ ЗАХВОРЮВАНЬ І ПОРУШЕНЬ СТАНУ ЗДОРОВ'Я

Info

Publication number
UA110463C2
UA110463C2 UAA201202214A UAA201202214A UA110463C2 UA 110463 C2 UA110463 C2 UA 110463C2 UA A201202214 A UAA201202214 A UA A201202214A UA A201202214 A UAA201202214 A UA A201202214A UA 110463 C2 UA110463 C2 UA 110463C2
Authority
UA
Ukraine
Prior art keywords
pharmaceutical composition
methoxt
benzazipine
pyrimido
methoxyphenyl
Prior art date
Application number
UAA201202214A
Other languages
English (en)
Russian (ru)
Inventor
Vijayalakshmi Ramanan
Irene Sophie Tobias
Dauntel Specht Verwijs
Raymond D Skwierczynski
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42697590&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA110463(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of UA110463C2 publication Critical patent/UA110463C2/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)
UAA201202214A 2009-07-31 2010-07-28 ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ 4-{[9-ХЛОР-7-(2-ФТОР-6-МЕТОКСИФЕНІЛ)-5Н-ПІРИМІДО[5,4-d][2]БЕНЗАЗЕПІН-2-ІЛ]АМІНО}-2-МЕТОКСИБЕНЗОЙНОЇ КИСЛОТИ ДЛЯ ЛІКУВАННЯ РАКУ Й ІНШИХ ЗАХВОРЮВАНЬ І ПОРУШЕНЬ СТАНУ ЗДОРОВ'Я UA110463C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23021209P 2009-07-31 2009-07-31
PCT/US2010/002109 WO2011014248A1 (en) 2009-07-31 2010-07-28 Pharmaceutical compositions for the treatment of cancer and other diseases or disorders

Publications (1)

Publication Number Publication Date
UA110463C2 true UA110463C2 (ru) 2016-01-12

Family

ID=42697590

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201202214A UA110463C2 (ru) 2009-07-31 2010-07-28 ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ 4-{[9-ХЛОР-7-(2-ФТОР-6-МЕТОКСИФЕНІЛ)-5Н-ПІРИМІДО[5,4-d][2]БЕНЗАЗЕПІН-2-ІЛ]АМІНО}-2-МЕТОКСИБЕНЗОЙНОЇ КИСЛОТИ ДЛЯ ЛІКУВАННЯ РАКУ Й ІНШИХ ЗАХВОРЮВАНЬ І ПОРУШЕНЬ СТАНУ ЗДОРОВ'Я

Country Status (30)

Country Link
US (3) US20110039826A1 (enExample)
EP (1) EP2459173B1 (enExample)
JP (2) JP2013500965A (enExample)
KR (1) KR101762285B1 (enExample)
CN (2) CN102548539A (enExample)
AR (1) AR077436A1 (enExample)
AU (1) AU2010276741B2 (enExample)
BR (1) BR112012002265B8 (enExample)
CA (1) CA2769531C (enExample)
CL (1) CL2012000261A1 (enExample)
CO (1) CO6612185A2 (enExample)
CR (1) CR20120084A (enExample)
EA (1) EA025277B1 (enExample)
EC (1) ECSP12011703A (enExample)
GE (1) GEP201606513B (enExample)
IL (1) IL217839A (enExample)
IN (1) IN2012DN01237A (enExample)
JO (1) JO3434B1 (enExample)
MA (1) MA33533B1 (enExample)
MX (2) MX348197B (enExample)
MY (1) MY174084A (enExample)
NZ (1) NZ598096A (enExample)
PE (1) PE20120788A1 (enExample)
SG (2) SG10201404483VA (enExample)
TN (1) TN2012000046A1 (enExample)
TW (1) TWI522357B (enExample)
UA (1) UA110463C2 (enExample)
UY (1) UY32822A (enExample)
WO (1) WO2011014248A1 (enExample)
ZA (1) ZA201200944B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1771450T3 (pl) * 2004-05-14 2008-05-30 Millennium Pharm Inc Związki i sposoby do inhibicji postępu mitozy przez hamowanie kinazy Aurora
AU2009330727B2 (en) * 2008-12-22 2016-07-28 Millennium Pharmaceuticals, Inc. Combination of Aurora kinase inhibitors and anti-CD20 antibodies
JO3635B1 (ar) 2009-05-18 2020-08-27 Millennium Pharm Inc مركبات صيدلانية صلبة وطرق لانتاجها
JO3434B1 (ar) 2009-07-31 2019-10-20 Millennium Pharm Inc مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري
TWI392514B (zh) * 2010-01-29 2013-04-11 Colgate Palmolive Co 具有高微生物效力之不含氟化物及陰離子表面活性劑的潔牙劑
WO2011103089A1 (en) 2010-02-19 2011-08-25 Millennium Pharmaceuticals, Inc. Crystalline forms of sodium 4-{[9-chloro-7-(2-fluoro-6--methoxyphenyl)-5h -pyrimido[5,4-d][2]benzazepin-2yl]amino}-2-methoxybenzoate
AR086656A1 (es) 2011-06-03 2014-01-15 Millennium Pharm Inc Combinacion de inhibidores de mek e inhibidores selectivos de la quinasa aurora a
US20130303519A1 (en) 2012-03-20 2013-11-14 Millennium Pharmaceuticals, Inc. Methods of treating cancer using aurora kinase inhibitors
CN105209042B (zh) 2013-03-22 2019-03-08 米伦纽姆医药公司 催化性mtorc 1/2抑制剂与选择性极光a激酶抑制剂的组合
JP6525474B2 (ja) 2013-12-06 2019-06-05 ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. オーロラキナーゼ阻害剤と抗cd30抗体の併用
US20180207173A1 (en) 2015-07-21 2018-07-26 Millennium Pharmaceuticals, Inc. Administration of aurora kinase inhibitor and chemotherapeutic agents
USD797120S1 (en) 2015-08-28 2017-09-12 Samsung Electronics Co., Ltd. Display screen or portion thereof with graphical user interface
WO2025075211A1 (en) 2023-10-03 2025-04-10 Takeda Pharmaceutical Company Limited Alisertib and paclitaxel for treating small cell lung cancer
WO2025245045A1 (en) 2024-05-21 2025-11-27 The Regents Of The University Of California Methods of treating lung cancer

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747487A (en) * 1993-07-29 1998-05-05 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
US6057329A (en) 1996-12-23 2000-05-02 Celltech Therapeutics Limited Fused polycyclic 2-aminopyrimidine derivatives
AU784971B2 (en) 1999-08-11 2006-08-10 Biogen Inc. Treatment of patients having non-Hodgkins lymphoma with bone marrow involvement with anti-CD20 antibodies
AR027714A1 (es) * 2000-03-24 2003-04-09 Baker Norton Pharma Uso de sales metalicas para estabilizar composiciones de taxanos.
US6982253B2 (en) * 2002-06-05 2006-01-03 Supergen, Inc. Liquid formulation of decitabine and use of the same
PL1771450T3 (pl) * 2004-05-14 2008-05-30 Millennium Pharm Inc Związki i sposoby do inhibicji postępu mitozy przez hamowanie kinazy Aurora
US20070104785A1 (en) * 2005-07-29 2007-05-10 Navale Suryakant V Tablets of linezolid form iii and processes for their preparation
ES2408318T3 (es) * 2005-12-23 2013-06-20 Glaxosmithkline Llc Inhibidores de azaindol de las cinasas Aurora
US20080004286A1 (en) 2006-06-30 2008-01-03 Schering Corporation Method of Using Substituted Piperidines that Increase P53 Activity
DK2046292T3 (da) * 2006-07-21 2010-06-07 Novartis Ag Formuleringer for benzimidazolylpyridylethere
JP2010500352A (ja) * 2006-08-09 2010-01-07 ミレニアム・ファーマシューティカルズ・インコーポレイテッド 有糸分裂の進行を阻止するためのピリドベンゾアゼピン化合物および方法
CL2007003244A1 (es) * 2006-11-16 2008-04-04 Millennium Pharm Inc Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
US20090203671A1 (en) * 2007-11-27 2009-08-13 Abbott Laboratories Method of treating cancer
AU2009330727B2 (en) * 2008-12-22 2016-07-28 Millennium Pharmaceuticals, Inc. Combination of Aurora kinase inhibitors and anti-CD20 antibodies
JO3635B1 (ar) * 2009-05-18 2020-08-27 Millennium Pharm Inc مركبات صيدلانية صلبة وطرق لانتاجها
JO3434B1 (ar) 2009-07-31 2019-10-20 Millennium Pharm Inc مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري
WO2011103089A1 (en) * 2010-02-19 2011-08-25 Millennium Pharmaceuticals, Inc. Crystalline forms of sodium 4-{[9-chloro-7-(2-fluoro-6--methoxyphenyl)-5h -pyrimido[5,4-d][2]benzazepin-2yl]amino}-2-methoxybenzoate

Also Published As

Publication number Publication date
US20160158244A1 (en) 2016-06-09
BR112012002265B8 (pt) 2021-05-25
TN2012000046A1 (en) 2013-09-19
CA2769531A1 (en) 2011-02-03
PE20120788A1 (es) 2012-07-22
US20140073630A1 (en) 2014-03-13
MX348197B (es) 2017-06-05
SG10201404483VA (en) 2014-10-30
MX2012001196A (es) 2012-03-14
JO3434B1 (ar) 2019-10-20
CL2012000261A1 (es) 2012-08-03
IN2012DN01237A (enExample) 2015-05-15
MA33533B1 (fr) 2012-08-01
TW201107331A (en) 2011-03-01
AR077436A1 (es) 2011-08-24
EP2459173A1 (en) 2012-06-06
IL217839A0 (en) 2012-03-29
UY32822A (es) 2011-01-31
CN102548539A (zh) 2012-07-04
BR112012002265A2 (pt) 2016-06-14
US20110039826A1 (en) 2011-02-17
EA025277B1 (ru) 2016-12-30
JP2015091877A (ja) 2015-05-14
EP2459173B1 (en) 2018-02-28
TWI522357B (zh) 2016-02-21
CR20120084A (es) 2012-06-01
GEP201606513B (en) 2016-07-25
KR101762285B1 (ko) 2017-07-28
BR112012002265B1 (pt) 2021-01-12
CN103893186B (zh) 2019-07-09
US9504693B2 (en) 2016-11-29
JP2013500965A (ja) 2013-01-10
NZ598096A (en) 2014-05-30
US9127011B2 (en) 2015-09-08
CN103893186A (zh) 2014-07-02
CO6612185A2 (es) 2013-02-01
CA2769531C (en) 2017-11-07
EA201270205A1 (ru) 2012-07-30
IL217839A (en) 2017-01-31
JP6014695B2 (ja) 2016-10-25
ECSP12011703A (es) 2012-03-30
AU2010276741A1 (en) 2012-03-01
KR20120053008A (ko) 2012-05-24
SG177751A1 (en) 2012-02-28
WO2011014248A1 (en) 2011-02-03
MY174084A (en) 2020-03-09
ZA201200944B (en) 2015-07-29
AU2010276741B2 (en) 2016-07-14

Similar Documents

Publication Publication Date Title
UA110463C2 (ru) ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ 4-{[9-ХЛОР-7-(2-ФТОР-6-МЕТОКСИФЕНІЛ)-5Н-ПІРИМІДО[5,4-d][2]БЕНЗАЗЕПІН-2-ІЛ]АМІНО}-2-МЕТОКСИБЕНЗОЙНОЇ КИСЛОТИ ДЛЯ ЛІКУВАННЯ РАКУ Й ІНШИХ ЗАХВОРЮВАНЬ І ПОРУШЕНЬ СТАНУ ЗДОРОВ'Я
EA201101243A1 (ru) 3h-имидазо[4,5-c]пиридин-6-карбоксамиды в качестве противовоспалительных средств
FI3504187T3 (fi) Pridopidiinin käyttö toiminnallisen heikkenemisen hoitoa varten
EA201290171A1 (ru) Вводимые перорально кортикостероидные композиции
AR060019A1 (es) Composicion farmaceutica, producto y metodo de tratamiento para un trastorno cognitivo y usos de un inhibidor de acetilcolinesterasa y un antagonista de 5- ht6 en la fabricacion de un medicamento para el tratamiento de un trastorno cognitivo
WO2007127635A3 (en) Diketo-piperazine and piperidine derivatives as antiviral agents
ECSP034571A (es) Nuevas composiciones de medicamentos a base de sales de tiotropio y sales del salmeterol
MX363023B (es) Formulaciones orales de analogos de citidina y metodos para usar los mismos.
MX2009003372A (es) Formas de dosificacion de pelicula no mucoadhesiva.
SE0401342D0 (sv) Therapeutic compounds
WO2008154083A3 (en) Compounds, compositions and methods for the treatment of synucleinopathies
UA107578C2 (uk) Комбінована терапія при лікуванні діабету
UA102517C2 (ru) Замещенные производные морфолина и тиоморфолина, фармацевтическая композиция на их основе и их применение для производства лекарственного средства для лечения расстройства или заболевания центральной нервной системы
ITBO20110012A1 (it) Composizioni farmaceutiche comprendenti rifaximina e loro uso.
UY27627A1 (es) Aza - arilpiperazinas
MX2012000275A (es) Antagonista de bomba de acido para el tratamiento de enfermedades involucradas en la motilidad gastrointestinal anormal.
BR0309185A (pt) Medicamento contendo beta-miméticos e um novo anticolinérgico
BRPI0411098A (pt) benzofuranocarboxamidas, com atividade pi3k, como agentes terapêuticos
ATE443722T1 (de) Peptide und peptidderivate, ihre herstellung sowie ihre verwendung zur herstellung einer therapeutisch und/oder prophylaktisch wirksamen pharmazeutischen zusammensetzung
SG158863A1 (en) Intravenous formulations of pde-5 inhibitors
ECSP045355A (es) Medicamento que contiene esteroides y un nuevo anticolinérgico
MX2009006454A (es) Derivados de espiro-piperidina.
ATE466574T1 (de) Verfahren und zusammensetzungen zur oralen fts- abgabe
ECSP099082A (es) Beta-agonistas enantioméricamente puros, procedimientos para su preparación y su uso como medicamentos
UY27670A1 (es) Nuevas composiciones de medicamentos sobre la base de agentes anticolinérgicos y de agentes inhibidores de la cinasa del egfr